1 July 2020 in Radiotherapy and Oncology
15 July 2019 in Acta Oncologica
Glioblastoma (GBM) is the most aggressive malignant brain tumor leading to a dismal prognosis. The median overall survival (OS) is only 15 months despite extensive tri-modality treatment. The curre...
22 May 2025 in Radiotherapy and Oncology
Robust quality assurance (QA) of clinical trials in radiotherapy (RT) is paramount for minimising uncertainties in treatment delivery, thereby strengthening the statistical power of the study and increasing the likelihood of accurately answering the research question. As RT techniques evolve and become more complex, establishing an appropriate QA program for a specific clinical trial becomes increasingly challenging, highlighting the importance of clear and standardised recommendations. This study provide such recommendations for Principal Investigators (PIs) to consider when planning and conducting RT Quality Assurance (RTQA) for clinical trials. They arise from experiences with RTQA in the clinical trials conducted in the Danish Multidisciplinary Cancer Groups (DMCGs). The recommendations include a checklist to guide PIs in developing an effective RTQA program.
1 September 2025 in Neuro-Oncology Practice
Background: IDH-mutant (mIDH) gliomas affect relatively young and otherwise healthy patients with high workforce participation. Management typically involves surgery, radiotherapy, and/or chemotherapy (RT/CT), although immediate post-surgery treatment may be deferred in favor of active observation (AO) to preserve functioning. This study aimed to evaluate how disease progression and treatments impact work activity, medical and societal costs, and overall survival (OS) in grade 2 mIDH glioma patients initially managed with AO. Methods: This retrospective longitudinal study utilized Danish administrative registries. Patients with mIDH gliomas initially managed with AO between 2010 and 2022 were included. Employment rates, sick leaves, treatment patterns, medical resources and costs, and OS were examined from diagnosis to the end of follow-up or death. Results: Data from 237 patients were analyzed; 72.9% were alive at 10 years. After surgical recovery, ability to work was most impaired during RT/CT, necessitating nearly full-time sick leave. Work activity continuously decreased after each RT/CT treatment. Employment rates were similarly affected, from under 20% unemployment at baseline and during AO, up to 41% and 59% after first and second RT/CT. Similar trends were observed for medical resources and costs, and productivity losses. Conclusions: Patients with grade 2 mIDH glioma remain active at work after initial surgery when managed with AO. Work impairment increases over successive RT/CT courses, highlighting the need to preserve quality of life by integrating work ability into clinical practice and by developing new treatment strategies to delay aggressive therapies and avoid substantial medical and productivity costs.
6 November 2024 in Clinical Oncology
Diffuse midline glioma (DMG) continues to be an aggressive brain stem cancer among children and young adults. It has a dismal prognosis, with less than 10% of patients alive two years after diagnosis. Radiotherapy has been demonstrated to be effective, albeit transient. Hence, radiotherapy is considered a cornerstone in the treatment. Reirradiation has, in retrospective studies, shown promising overall survival and palliative effect, but no pan-European consensus for reirradiation exists. The REMIT (Reirradiation of diffuse Midline glioma paTients) protocol evaluates safety and the palliative efficacy of reirradiation of patients with DMG (clinicaltrials.gov NCT06093165). Patients included in the protocol will be followed with 1) performance status (Karnofsky or Lansky), 2) toxicity monitored with Common Terminology Criteria for Adverse Events (CTCAE), 3) motor and functioning skill with PEDI-CAT (The Pediatric Evaluation of Disability Inventory) and 4) quantification of corticosteroid use. Furthermore, the impact on quality of life and well-being will be assessed qualitatively with interviews as well as with the Pediatric Quality of Life Inventory (PedsQl) Cancer Module questionnaire. The protocol also includes dose accumulation and contouring studies to assess standardization as well as a prescreening log to address selection bias of patients. The safety and palliative efficacy of reirradiation in DMG will be prospectively evaluated, including qualitative patient reported outcomes, through the REMIT protocol. REMIT is planned to open for inclusion in 2024.
21 July 2025 in Acta Oncologica
JKJesper Folsted Kallehauge
Jesper Folsted Kallehauge
CBCamilla Skinnerup Byskov
Background and purpose: The selection of patients with low-grade gliomas for proton therapy (PT) is often based on the comparison of photon and PT plans and demonstrating meaningful dose reduction to the healthy brain or critical structures. The aim of this retrospective study was to identify clinical parameters associated with referral to PT and build a prediction model. Patients and methods: The dataset consisted of patients with isocitrate dehydrogenase (IDH)-mutant grades 2 and 3 glioma and candidates for PT at the Aarhus University Hospital. Clinical (age, diagnosis, clinical target volume [CTV], and treatment) and dosimetric (prescribed dose and mean dose (Dmean) to healthy brain) parameters were collected. Univariate and multivariate logistic regression were used to assess the association with selection for PT. The dataset was split into training (n = 37, period 2019–2022) and test (n = 12, period 2023) cohorts. Prediction models were built using logistic regression algorithms and support vector machines (SVMs) and evaluated using the area under the precision-recall curve (AUC-PR). Results: Age (p = 0.03) and CTV (p = 0.01) were significantly associated with the selection for PT and were used for model prediction. The logistic regression demonstrated AUC-PR at 0.999 (CI 0.999–1.000) and 0.998 (0.996–1.000) for training and test cohorts, respectively. SVM showed similar results with AUC-PR at 0.993 (0.993–0.994) for training and 0.999 (0.998–1.000) for test cohorts. Interpretation: Logistic regression and SVM using age and CTV performed equally well and achieved a very high positive predictive value. With the pending external validation in a larger dataset, the prospects of this work suggest more consistent and efficient patient referral for PT.